# RNN 2nd Gen Model Perrigo Company Pharmaceutical preparations

Stock predictor AI models:
Subscribe >> Deal exit on
Dec. 14, 2020
Deal entry on
Dec. 14, 2020
1.73%Expected margin
71.74% successful of 92 deals
$ 42.09 Last close price
at 02-mar-2021

PRGO

Model's trade recommendations 2.12% Return for period

-8.12% Annual return

$10.75B Market Cap

β 0.77  

PRGO

Model (following trade recommendations)

PRGO

Underlying stock

S&P 500

Index
Return for period 2.12%
-0.57%
1.78%
52wk return -11.99%
-21.08%
16.82%
52wk Range
40.36—58.54
2000.54—2399.63
Sortino ratio -0.29
Sharpe ratio -0.26
Norm. RMSE 0.37%
Downside risk 20.33%
Volatility 0.00%
  • 0.76 (1.00%) Div (Yield)
  • BUY Analysts consensus recommendation

Perrigo Company plc develops, manufactures and distributes healthcare products. The company operates primarily in four segments: Consumer Healthcare, Nutritionals, Rx Pharmaceutical and Active Pharmaceutical Ingredients. It also provides animal health products. The company operates primarily in the United States, the United Kingdom, Mexico, Israel, Australia, Canada, China and Latin America. Perrigo Company plc formerly known as Perrigo Company is headquartered in Ireland.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Perrigo Company (PRGO) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 30, 2015.

Market data for PRGO model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for PRGO.

Model is being retrained on a regular basis.

Float 131M
P/E 15.45
Shares Outstanding 141M
% Held by Insiders 6.90%
% Held by Institutions 79.12%
EPS (last reported FY) $4.93
EPS (last reported Q) $1.28
EPS, estimated (last reported Q) $1.24
Total revenues $5 B
Net income $0 B